• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Recall J&J breast implants, consumer groups tell FDA panel

Recall J&J breast implants, consumer groups tell FDA panel

August 31, 2011 By MassDevice staff

Silicone breast implants

Consumer groups asked the FDA to recall Johnson & Johnson’s (NYSE: JNJ) silicone breast implants over concerns that they haven’t collected postmarket data on the devices as promised.

JNJ’s Mentor division and Allergan Inc. (NYSE:AGN) won FDA clearance for silicone breast implants in 2006 on the condition that they would collect safety data on 40,000 patients for 10 years.

Allergan has collected data for 60 percent of its patients for two years, while JNJ has data on 21 percent of patients for three years.

Representatives from both companies said they may have "overreached" with their studies by attempting to follow so many patients and requiring them to fill out 27-page surveys each year.

JNJ also shifted their study participation from mandatory for all breast implant patients to voluntary participation.

"It’s unacceptable that many patients Mentor and Allergan were supposed to track were lost," National Organization for Women Foundation spokesperson Jan Erickson said. "Mentor’s approval should be rescinded right away. And Allergan should be required to conduct further studies."

The FDA released updated information about gel-filled breast implants in June, warning that they often cause complications that need additional surgery or removal, drawing from data provided by JNJ and Allergan who essentially control the breast implant market.

"The longer a woman has silicone gel-filled breast implants, the more likely she is to experience complications," the report noted, adding that 20 percent of implants used for augmentation will require removal within 10 years, as will half of implants used for reconstruction.

The revamped breast implant is safer than the last generation, which was pulled off the market in 1992 over fears of leakage, but the silicon prosthetics still come with risks, the FDA warned.

Common complications include hardened skin around the implant, wrinkled or ruptured implants, scarring, pain and infection. Some patients complained of these side effects at this week’s advisory panel.

The June report also noted that there was no established link between the silicon gel-filled breast implants and breast cancer, reproductive problems or connective tissue disease, but added that additional studies enrolling more women and running longer than the existing studies are needed to explore the possibility.

Consumer groups argued that the FDA needs to take a stronger hand in forcing the companies to adhere to the rules and provide postmarket study data.

"We believe that this agency has to walk the walk," National Physicians Alliance executive director Jean Silver-Isenstadt told Reuters. "Its mission is to protect patients, and when it sets criteria for approval, that should be real. When the agency begins to look more like window-dressing (for companies), that will shake the faith of physicians and patients."

The FDA panel is set to make recommendations on postmarket studies later today.

Filed Under: Food & Drug Administration (FDA), Implants, News Well, Recalls, Women's Health Tagged With: Allergan, Johnson and Johnson

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy